Premium
Assessment of the clinical and virological protection provided by a commercial inactivated bovine viral diarrhoea virus genotype 1 vaccine against a BVDV genotype 2 challenge
Author(s) -
Hamers C.,
Couvreur B.,
Dehan P.,
Letellier C.,
Fischer L.,
Brun A. J.,
Lewalle P.,
Michaux C.,
Pastoret PP.,
Kerkhofs P.
Publication year - 2003
Publication title -
veterinary record
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 99
eISSN - 2042-7670
pISSN - 0042-4900
DOI - 10.1136/vr.153.8.236
Subject(s) - genotype , virology , vaccination , virus , biology , pestivirus , inactivated vaccine , vaccine efficacy , strain (injury) , nasal administration , medicine , viral disease , flaviviridae , gene , biochemistry , anatomy
A new genotype of bovine viral diarrhoea virus (BvDv), designated BVDV‐2, has emerged in the last decade and in recent years the prevalence of BVDV‐2 strains has increased. A vaccination‐challenge study was carried out to determine the cross‐protective efficacy of a commercial inactivated vaccine containing a BVDV‐1 strain. A group of five BVDv‐free calves was vaccinated twice and a second group of five calves served as negative controls. Two months after the first vaccination, all the calves were challenged intranasally with BVDV‐2 strain BVD890. The clinical signs of disease, the changes in haematological variables and the level of viraemia were significantly less in the vaccinated group.